Lymphangioleiomyomatosis (LAM) Research Study
|
Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Research Study
|
If you have been diagnosed with Lymphangioleiomyomatosis (or LAM) or with tuberous sclerosis complex (TSC), you may be eligible to participate in a research study at the NIH Clinical Center. The purpose of this research study is to improve our understanding of LAM and TSC. Eligible patients undergo a comprehensive pulmonary evaluation at the Clinical Center in Bethesda, MD.
There is no cost to you for travel or medical testing and, should you wish, information from your evaluation will be provided for your physicians.
For further information, please contact our research coordinator at toll free telephone: 1-877-NIH-LUNG (1-877-644-5864), extension 3, email: LungStudy@nhlbi.nih.gov.
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Lymphangioleiomyomatosis (LAM) Research Study
|
Lymphangioleiomyomatosis (LAM) Treatment Research Study
|
If you have been diagnosed with lymphangioleiomyomatosis and have developed fluid in the lungs (chylous effusions), you may be eligible to participate in our research study. If eligible, you will undergo a comprehensive pulmonary and medical evaluation at the Clinical Center in Bethesda, MD. The purpose of this study is to test the effectiveness of a medication called octreotide on symptoms and chylous effusions. Octreotide is a medicine, that in other studies was helpful in reducing chylous ascites, effusions and other disorders associated with lymphatic flow.
There is no cost to you for travel or medical testing, and should you wish, information from your evaluation will be provided for your physicians.
For further information, please contact our research coordinator at toll free telephone: 1-877-NIH-LUNG (1-877-644-5864),
extension 3, or e-mail:LungStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute